Regenerative Medical Services receives DCGI nod for cell therapy product

The Mumbai-based Regenerative Medical Services Regrow (RMS Regrow) has received market authorisation for India’s first cell therapy product, Chondron ACI, from Drug Controller General of India (DCGI), which works under the Central Drugs Standard Control Organization (CDSCO).

Chondron ACI is indicated for treatment of cartilage defects of the joints. It uses the body's own autologous cartilage cells which are cultured and multiplied for 3-4 weeks at Regrow’s cell processing centre. The cultured cells are then implanted into the patient's damaged joint leading to new cartilage regeneration, avoiding the need of early joint replacement.

“We are immensely happy with the FDA approval for